Document is current
Any future updates will be listed below
-
Authors
Peters, Jim https://orcid.org/0000-0002-6115-9678
van Leeuwen, Merle M.
Moriakov, Nikita
van Dijck, Jos A. A. M.
Mann, Ritse M.
Teuwen, Jonas
Lips, Esther H. https://orcid.org/0000-0003-3488-4935
van den Belt-Dusebout, Alexandra W. https://orcid.org/0000-0002-7860-8839
Wesseling, Jelle https://orcid.org/0000-0002-8940-2676
Penning de Vries, Bas B. L.
Verboom, Sarah
Karssemeijer, Nico
Elias, Sjoerd G.
Broeders, Mireille J. M. https://orcid.org/0000-0002-8741-8148
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (11835, 11835, 11835, 11835, 11835, 11835, 11835, 11835, 11835, 11835, 11835, 11835, 11835)
- License Information
-
More Information
Article History
Received: 13 March 2024
Revised: 17 January 2025
Accepted: 21 March 2025
First Online: 6 April 2025
Competing interests
: The authors declare the following relationships: N.K. is board member and shareholder of ScreenPoint Medical and shareholder of Volpara Technology. RM. received research grants or equipment from Bayer, Siemens, ScreenPoint Medical, Koning, Becton Dickinson, PA Imaging and Lunit and provided consultancy for ScreenPoint Medical, Becton Dickinson, Bayer, Guerbet, Bracco and Siemens. All other authors declare no potential conflict of interest
: This study was conducted in accordance with the declaration of Helsinki. No explicit written or verbal consent was obtained, but consent was obtained through an opt-out procedure that exists in the Dutch screening program. When participating in the program, women are informed that their data can be used for evaluation of the program or scientific purposes to improve the program. If women chose to opt-out, their data was not used. The Radboud university medical center ethics committee declared that this study falls outside the scope of the Dutch Medical Research involving Human Subjects Act and could be carried out without approval of an Institutional Review Board.
